Currently set to Index
Currently set to Follow
search
ask age2b
CART 0

Science Diabetes mellitus

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
November 7, 2021
0
0
Husam Ghanim 1, Sanaa Abuaysheh 1, Jeanne Hejna 1, Kelly Green 1, Manav Batra 1, Antione Makdissi 1, Ajay Chaudhuri 1, Paresh Dandona 1 Main idea: We conclude that dapagliflozin increases erythropoiesis and hematocrit through mechanisms that involve the suppression of hepcidin and the modulation of other iron regulatory proteins. Abstract Context: Dapagliflozin and other […]
Read more
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
November 7, 2021
0
0
Juan Carlos Hidalgo Santiago 1, Juan Maraver Delgado 2, Manuel Cayón Blanco 3, Juan Bosco López Saez 4, Pablo Gómez-Fernández 5 Main idea: Dapagliflozin, in subjects with DM2, produces a medium to long-term decrease in arterial stiffness. Abstract Introduction: Oral antidiabetic inhibitors of the sodium-glucose cotransporter (SGLT2i) reduce cardiovascular morbidity and mortality in DM2. The […]
Read more
Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects
November 7, 2021
0
0
Monica Shah 1, May M Adel 1, Bettina Tahsin 1, Yannis Guerra 1, Leon Fogelfeld 1 Main idea: Contrary to the assumption that insulin resistance is the main driver of glucocorticoid-induced hyperglycemia, results indicate that decreased beta-cell insulin secretion is the more likely cause in those with T2DM. These results may be caused by increased […]
Read more
Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes
November 7, 2021
0
0
Qianhui Zhang 1, Yanhong Wei 1, Min Chen 1, Qianqian Wan 1, Xiaoqi Chen 2 Main idea: Type 2 diabetic patients were more susceptible to COVID-19 than overall population, which might be associated with hyperglycemia and dyslipidemia. Aggressive treatment should be suggested, especially when these patients had low CD4+T lymphocyte counts and high SAA levels. […]
Read more
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
November 7, 2021
0
0
Ildiko Lingvay 1, Nadine Beetz 2, Regina Sennewald 2, Annette Schuler-Metz 3, Julia Bertulis 3, Christina Loley 4, Benjamin Lang 4, Caroline Lippert 3, Jisoo Lee 5, Linda Shapiro Manning 6, Derek Terada 6 Main idea: The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations. Based on these two […]
Read more
Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome
November 7, 2021
0
0
Jean Ferrières 1, Dominik Lautsch 2, Peter Bramlage 3, Martin Horack 4, Carl A Baxter 5, Baishali Ambegaonkar 2, Peter P Toth 6, Kian-Keong Poh 7, Gaetano Maria De Ferrari 8, Anselm K Gitt 9 Main idea: Despite the different lipid profiles, the type of LLT prescribed did not vary depending on the presence or […]
Read more
Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
November 7, 2021
0
0
Di Zhao 1, Hui Liu 2, Pingshuan Dong 3 Main idea: This data suggest the beneficial effects of liraglutide on cardiovascular protection and may improve prognosis in these patients. Abstract The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects […]
Read more
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
November 7, 2021
0
0
Kausik K Ray 1, Stephen J Nicholls 2, Kevin A Buhr 3, Henry N Ginsberg 4, Jan O Johansson 5, Kamyar Kalantar-Zadeh 6, Ewelina Kulikowski 5, Peter P Toth 7, Norman Wong 5, Michael Sweeney 5, Gregory G Schwartz 8, BETonMACE Investigators and Committees Main idea: Among patients with recent acute coronary syndrome, type 2 […]
Read more
Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis
November 7, 2021
0
0
Osamah M Alfayez 1, Omar A Almohammed 2, Omar S Alkhezi 1, Abdulaali R Almutairi 3, Majed S Al Yami 4 Main idea: The GLP1RAs have shown significant benefits in terms of CV safety. The indirect comparison and ranking probability results have shown that one weekly semaglutide and oral semaglutide seems to be the preferred […]
Read more
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
November 7, 2021
0
0
Geltrude Mingrone 1, Simona Panunzi 2, Andrea De Gaetano 2, Caterina Guidone 3, Amerigo Iaconelli 3, Esmeralda Capristo 3, Ghassan Chamseddine 4, Stefan R Bornstein 5, Francesco Rubino 6 Main idea: Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes. Clinicians and policy makers should ensure that […]
Read more

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.